Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL288973 | 0.93 | — | — | |
| Dimethylformamide SCHEMBL11280350 | 0.90 | — | — | |
| Dimethylformamide SCHEMBL850064 | 0.86 | — | — | |
| Dimethylformamide SCHEMBL6351192 | 0.83 | — | — | |
| Dimethylformamide SCHEMBL28844186 | 0.83 | — | — | |
| Dimethylformamide SCHEMBL28266476 | 0.82 | — | — | |
| Dimethylformamide SCHEMBL3867818 | 0.82 | — | — | |
| Dimethylformamide SCHEMBL28003911 | 0.82 | — | — | |
| Dimethylformamide SCHEMBL29240608 | 0.81 | — | — | |
| Dimethylformamide SCHEMBL5750706 | 0.80 | TSHR (0.60) | TSHRUSP2ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499147-A2 | IMPROVED PROCESSES FOR PREPARING PRASUGREL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEROEOF | MSN Laboratories Limited (IN) | 2012-09-19 | — | — | EP | claimed |
| US-20120202066-A1 | Processes For Preparing Prasugrel And Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-08-09 | — | — | US | claimed |
| WO-2011042918-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PRASUGREL, ITS INTERMEDIATES AND PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-04-14 | — | — | WO | claimed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-6329193-B1 | A PURE CULTURE OF A FUNGUS, TAXOMYCES, PRODUCING TAXOL OR TAXANE IN THE CULTURE MEDIUM; THERAPY FOR CANCER AND LEUKEMIA | THE RESEARCH AND DEVELOPMENT INSTITUTE AT MONTANA STATE UNIVERSITY | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | TSHR 4762/4885USP2 3271/4885ALOX15 2464/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | TSHR 3117/4885USP2 2570/4885ALOX15 4123/4885 |
| US-20120202066-A1 | Processes For Preparing Prasugrel And Pharmaceutically Acceptable Salts Thereof | SF1, PFKP, CYP2F1 | TSHR 4275/4885USP2 4308/4885ALOX15 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.